Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry

Yun Ma,1* Haibin Su,1,2* Muhammed Yuksel,1,3 Maria Serena Longhi,1,4 Mark J. McPhail,1 Pengyun Wang,1 Sanjay Bansal,5 Guan-Wee Wong,1,6 Jonathon Graham,1,6 Li Yang,6,7 Richard J. Thompson,1,5 Derek G. Doherty,8 Nedim Hadzic,5 Yoh Zen,1 Alberto Quaglia,1,9 Michael A. Heneghan,1 Marianne Samyn,5a Diego Vergani,1* and Giorgina Mieli-Vergani1,5a

BACKGROUND AND AIMS: Genetic predisposition to autoimmune hepatitis (AIH) in adults is associated with possession of human leukocyte antigen (HLA) class I (A*01, B*08) and class II (DRB1*03, -04, -07, or -13) alleles, depending on geographic region. Juvenile autoimmune liver disease (AILD) comprises AIH-1, AIH-2, and autoimmune sclerosing cholangitis (ASC), which are phenotypically different from their adult counterparts. We aimed to define the relationship between HLA profile and disease course, severity, and outcome in juvenile AILD.

APPROACH AND RESULTS: We studied 236 children of European ancestry (152 female [64%], median age 11.15 years, range 0.8-17), including 100 with AIH-1, 59 with AIH-2, and 77 with ASC. The follow-up period was from 1977 to June 2019 (median 14.5 years). Class I and II HLA genotyping was performed using PCR/sequence-specific primers. HLA B*08, -DRB1*03, and the A1-B8-DR3 haplotype impart predisposition to all three forms of AILD. Homozygosity for DRB1*03 represented the strongest risk factor (8.8). HLA DRB1*04, which independently confers susceptibility to AIH in adults, was infrequent in AIH-1 and ASC, suggesting protection; and DRB1*15 (DR15) was protective against all forms of AILD. Distinct HLA class II alleles predispose to the different subgroups of juvenile AILD: DRB1*03 to AIH-1, DRB1*13 to ASC, and DRB1*07 to AIH-2. Possession of homozygous DRB1*03 or of DRB1*13 is associated with fibrosis at disease onset, and possession of these two genes in addition to DRB1*07 is associated with a more severe disease in all three subgroups.

CONCLUSIONS: Unique HLA profiles are seen in each subgroup of juvenile AILD. HLA genotype might be useful in predicting responsiveness to immunosuppressive treatment and course. (HEPATATOLOGY 2021;0:1-15).

Genetic predisposition to autoimmune hepatitis (AIH), a progressive inflammatory liver disease with a female preponderance, has been associated with alleles of the major histocompatibility complex (MHC) class I and II genes in adult patients. Susceptibility to type 1 AIH (AIH-1), which is the most common form of the disease, characterized by antinuclear antibodies (ANA) and/or anti–smooth muscle antibodies (SMA), has been linked to MHC class II human leukocyte antigen (HLA) DRB1 alleles encoding the similar amino acid sequences LLEKR and LLEQRR at positions 67-72 of the DRβ polypeptide. These motifs are encoded by the DRB1*0301 and DRB1*0401 alleles, which...
predispose adults of European ancestry from northern Europe, North America, and Iran to AIH-1; by \(\text{DRB1}^*0405\), the susceptibility allele in Japan and Argentina; and by \(\text{DRB1}^*0404\), the AIH-1 predisposing allele in Mexico, although a recent investigation has questioned its role in susceptibility. A recent paper suggests the impact of specific killer cell Ig-like receptor/HLA pairs in conferring susceptibility and influencing disease progression in Japanese patients with AIH-1. \(\text{DRB1}^*1501\), which is associated with protection toward AIH-1, encodes alanine (A) at position 71, suggesting that the amino acid at this position is a primary determinant of disease susceptibility or resistance.

Childhood AIH differs from its adult counterpart in two key aspects: firstly, a third of patients are affected by AIH type 2 (AIH-2), characterized by positivity for anti–liver kidney microsomal type 1 (anti-LKM1) and/or anti–liver cytosol type 1 (anti-LC1) antibodies; secondly, some 50% of children with laboratory and histological features of AIH-1 (i.e. ANA and/or SMA positivity and interface hepatitis) have bile duct damage on cholangiography at disease onset and are diagnosed as having autoimmune sclerosing cholangitis (ASC).

Reports of MHC-encoded disease susceptibility in pediatric autoimmune liver disease (AILD) have been limited to either small numbers of patients or AIH subgroups and have not differentiated AIH-1 from ASC. Reported HLA associations in childhood AIH are summarized in Supporting Table S1. Of note, in contrast to adult patients, the \(\text{DRB1}^*0401\) allele is not a predisposing factor and can even exert a protective role, and the \(\text{DRB1}^*1301\) allele reported to predispose to AIH-1 in Argentinian and Venezuelan children does not conform to the shared motif model mentioned above, harboring the sequence LIEDER at positions 67-72.

The aim of the present study was to investigate the HLA profile and its influence on disease predisposition, course, severity, and outcome in a large series of children with AILD, including AIH and ASC, followed up at a single center, King’s College Hospital (KCH), London.

This paper is dedicated to Dr. James Underhill (J.U.), PhD, who performed over the years the HLA typing of our patients with autoimmune liver disease and who died untimely in 2015.

© 2021 The Authors. \textit{Hepatology} published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

View this article online at wileyonlinelibrary.com.
DOI 10.1002/hep.31893

Potential conflict of interest: Dr. Thompson consults for Mirum, Alibero, Sana, EVOX, and Alnylam. He consults for and owns stock in Generation Bio and Rectify Therapeutics. Dr. Hadzic consults for Arrowhead, Alnylam, and Alibero. He advises Takeda.

ARTICLE INFORMATION:

From the 1 Institute of Liver Studies, Mowat Labs, Department of Inflammation Biology, School of Immunology & Microbial Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, United Kingdom; 2 Department of Liver Disease of Chinese PLA General Hospital, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China; 3 Koc University Research Centre for Translational Medicine, Istanbul, Turkey; 4 Department of Anesthesia, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; 5 Paediatric Liver, GI and Nutrition Centre, King’s College Hospital, London, United Kingdom; 6 Department of Medicine, Ng Teng Fong General Hospital, Singapore; 7 Department of Gastroenterology & Hepatology, West China Hospital, Sichuan University, Chengdu, China; 8 Discipline of Immunology, School of Medicine, Trinity College Dublin, Dublin, Ireland; 9 Department of Cellular Pathology, Royal Free London NHS Foundation Trust, UCL Cancer Institute, Research Department of Pathology, London, United Kingdom.

ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:

Yun Ma, M.D., Ph.D.
Institute of Liver Studies, King’s College Hospital
Denmark Hill
London SE5 9RS, UK
E-mail: yun.ma@kcl.ac.uk
Tel.: +44 20 3299 1558
Patients and Methods

PATIENTS

A total of 236 unrelated children of European ancestry (152 female, 64%) fulfilling the criteria for the diagnosis of AILD according to the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) scoring system for juvenile AILD,(23) were referred to our center between 1977 and 2016 and followed up to 2019. Retrospective data were collected from 1977 to December 1999 for 116 patients. From January 2000 until June 2016, 120 patients were recruited prospectively, and their blood was collected with full consent for research, including HLA typing. The study was approved by the Ethics Committee of KCH. The informed consent in writing was obtained from each patient or their guardians since January 2000 and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the Ethics Committee of KCH. For retrospective data where informed consent was not possible, the requirement for informed consent was waived by the review committee of KCH.

To confirm the AILD diagnosis, all patients were scored retrospectively using the ESPGHAN diagnostic criteria.(23)

Four patients from abroad were lost to follow-up soon after diagnosis, while 232 patients were followed up until June 2019 (median 14.5 years, range 20 days-42 years, 3,489.5 person-years). Cholangiograms by endoscopic retrograde cholangiopancreatography or MR cholangiopancreatography to assess possible bile duct damage were performed in all patients, at or soon after presentation. One hundred patients had AIH-1 (median age at diagnosis 12 years, range 2.4-17), 77 had ASC (median age at diagnosis 11.3 years, range 2.1-15.7), and 59 had AIH-2 (median age 7.4 years, range 0.8-16). Viral hepatitis, Wilson disease, NASH, and other causes of liver disease were excluded by appropriate investigations. Laboratory, clinical, and histological indices were recorded in a dedicated database, those at the time of diagnosis being shown in Table 1. Two hundred and nine local subjects of European ancestry (110 female, 53%, median age 31 years, range 23-62) served as healthy controls (HCs), after providing informed consent.

Two national and one London-based population controls (predominantly of European ancestry), comprising 1,798, 2,041, and 935 subjects, respectively, served as references to our local HCs (Supporting Table S2).(24-26)

HLA DETERMINATION

HLA class I genotyping for 14 HLA A and 17 HLA B antigens and class II genotyping for 37 HLA DRB, 8 DQA, and 15 DQB antigens was performed by PCR/sequence-specific primers using kits obtained from Biotest (Dreiech, Germany).15,27 Alleles were assigned to broad antigens. HLA typing was carried out in the same laboratory, under similar conditions, and by the same investigator (J.U. who died untimely before the writing up of the paper and to whom the paper is dedicated), who was unaware of the diagnosis and the details of the patients.

DETECTION OF AUTOANTIBODIES

ANA, SMA, anti-LKM1, and anti-LC1 were tested by indirect immunofluorescence on a composite substrate including rat liver, kidney, and stomach at the initial dilution of 1/10 in phosphate-buffered saline according to the recommendations of the International Autoimmune Hepatitis Group.28,29 Positive sera were double-diluted to extinction. Titers of ≥1/20 were considered positive.28,29

STATISTICAL ANALYSIS

c2 and one-tailed Fischer exact tests were used to compare HLA frequencies in different groups. In order to control family-wise error rate for multiple testing, the Holm-Bonferroni correction was applied.30,31 Relative risk (RR) was calculated as ORs.31 The normality of variable distributions was tested using the Kolmogorov-Smirnov goodness-of-fit test. Differences in aspartate aminotransferase (AST), IgG, and bilirubin levels and autoantibody titers among patients with different HLA alleles were analyzed either by t test for parametric data or the Wilcoxon rank sum test for nonparametric data. Transplant-free survival in years from diagnosis was calculated by a Kaplan-Meier survival plot. P < 0.05 was considered significant.
### Results

#### CLINICAL DATA

Eight of 100 patients with AIH-1, 14/77 patients with ASC, and 6/59 patients with AIH-2 were already on immunosuppression for 3 months to 3 years before referral to KCH. Liver biopsy at presentation was performed in 216 patients (92%), before starting immunosuppressive treatment in 194 and within 6 months from starting treatment in 22 with coagulopathy, after prothrombin time normalization. In the remaining 20 patients, liver biopsies were performed ≥8 months after referral while on immunosuppression or in their local hospitals before referral and reported as compatible with AILD, but these were not available for review. Four out of 20 patients had complications of portal hypertension (hematemesis/melena from esophageal/gastric varices, bleeding diathesis, splenomegaly), and 16 had evidence of severe fibrosis by noninvasive tests, including ultrasound, showing nodular liver parenchyma and splenomegaly, FibroScan,

| Features | Median (Range) | AIH-1, n = 100; follow-up, n = 98 | P AIH-1 vs. ASC, n = 77; follow-up, n = 77 | P ASC vs. AIH-2, n = 59; follow-up, n = 57 | P AIH-2 vs AIH-1 |
|----------|----------------|----------------------------------|---------------------------------------------|---------------------------------------------|-----------------|
| Age      | 12 (2.4-17)    | NS                               | 11.3 (2.1-15.7)                             | 0.005                                       | 7.4 (0.8-16)    | 0.019 |
| Female, n (%) | 66 (66)       | 0.017                            | 37 (48)                                     | 0.00038                                     | 49 (83)         | NS    |
| Acute presentation, n (%) | 60 (60)        | NS                               | 38 (49)                                     | NS                                          | 37 (63)         | NS    |
| AST, IU/L (nv ≤ 50) | 591 (60-4.830) | NS                               | 258 (62-3.344)                             | 0.0045                                       | 548 (51-6.600)  | 0.0015 |
| AP, IU/L (nv ≤ 130) | 288 (66-1.587) | 0.02                             | 323 (72-1.243)                             | 0.004                                       | 221 (73-573)    | NS    |
| GGT, IU/L (nv ≤ 55) | 85 (20-656)   | 0.0002                           | 198 (13-623)                               | 0.0003                                       | 81 (6-225)      | NS    |
| IgG, g/L (nv 5-18) | 26.5 (9.55-68.9) | 0.03                            | 20.5 (7.81-63.7)                           | NS                                          | 16.9 (4.65-67.4) | 0.03 |
| ANA titer* | 160 (neg-10.240) | NS                            | 160 (neg-5.120)                            | NS                                          | 160 in one case | NS    |
| SMA titer* | 160 (neg-2.560) | NS                             | 160 (neg-1.280)                            | NS                                          | 20 in one case  | NS    |
| LKM1 titer* | Negative in all | NS                            | Negative in all                            | NS                                          | 1.280 (neg1-20480) | NS    |
| HAI       | 8 (1-17) (in 75 patients) | NS                        | Not applicable                             | NS                                          | 6 (1-17) (in 41 patients) | 0.05 |
| Fibrosis score | 4 (0-6)        | NS                              | Not applicable                             | NS                                          | 3 (0-6)         | 0.05 |
| Diagnostic score | 11 (7-14)      | 0.01                            | 8 (7-14)                                   | NS                                          | 10 (7-14)       | 0.01 |
| GRs, n (%) | 64/98 (65)     | NS                              | 43/77 (56)                                 | NS                                          | 30/57 (53)      | NS    |
| SRs, n (%) | 21/98 (21)     | NS                              | 14/77 (18)                                 | NS                                          | 10/57 (18)      | NS    |
| ESLD (LT and/or death), n (%) | 13/98 (13) | NS                            | 20/77 (26)                                 | NS                                          | 17/57 (30)      | NS    |
| Associated autoimmune disorders | 28 (28) | 3.92E7                          | 51 (66)                                    | 8.3E5                                       | 19 (32)         | NS    |
| Ulcerative colitis | 10            | 37                              | 1                                          | 1                                           | 1               | 1     |
| Crohn disease | 2             | 6                               | 1                                          | 1                                           | 1               | 1     |
| Indeterminate colitis | 1           | 1                               | 0                                          | 0                                           | 0               | 0     |
| Systemic lupus erythematosus | 4          | 2                               | 1                                          | 1                                           | 1               | 1     |
| Diabetes mellitus type 1 | 5            | 2                               | 9                                          | 9                                           | 9               | 9     |
| Autoimmune pancreatitis | 1            | 0                               | 0                                          | 0                                           | 0               | 0     |
| Celiac disease | 2             | 1                               | 1                                          | 1                                           | 1               | 1     |
| Sjogren syndrome | 1            | 0                               | 0                                          | 0                                           | 0               | 0     |
| Juvenile arthritis | 1            | 1                               | 2                                          | 2                                           | 2               | 2     |
| Autoimmune thyroiditis | 1            | 1                               | 2                                          | 2                                           | 2               | 2     |
| Autoimmune polyendocrine syndrome type 1 | 0         | 0                               | 2                                          | 2                                           | 2               | 2     |

Transaminase, bilirubin, IgG values and autoantibody titers of 28 patients treated with immunosuppression longer than 3 months before referral are not included in this table. HAI of 20 patients who did not undergo a liver biopsy before or shortly after starting immunosuppressive treatment are also not included in the table.

*Titers are shown as reciprocal values.

†Two cases being anti-LKM1-negative but anti-LC1-positive.

Abbreviations: neg, negative; NS, not significant; nv, normal value.
or MR elastography. All 216 patients biopsied at or within 6 months from diagnosis had histological features of interface hepatitis. At diagnosis, 170 patients had moderate to severe and 46 mild necroinflammation. For patients with AIH (75 AIH-1 and 41 AIH-2), severity of liver damage and degree of fibrosis were reviewed independently for the purpose of this study by two histopathologists (A.Q. and Y.Z.) and reported as histological activity index (HAI) and fibrosis score according to the Desmet and Ishak grading systems,(21,28) which record the degree of perportal or periseptal interface hepatitis, confluent necrosis, lytic necrosis, focal inflammation, portal inflammation, and fibrosis. These scoring systems were not applied to patients with ASC as they have not been validated for this condition. Ninety-eight patients (42%) had concurrent immune-mediated diseases, including type 1 diabetes, inflammatory bowel disease (IBD; ulcerative colitis, indeterminate colitis, or Crohn disease) or celiac disease (Table 1).

All patients were treated with prednisolone at a starting dose of 2 mg/kg/day (maximum 60 mg/day), weaned within 6-8 weeks to a maintenance dose of 2.5-5 mg/day according to child’s age and weight; azathioprine (1-2 mg/kg/day) was added in the absence of gradual improvement of transaminase levels on prednisolone alone. Patients with ASC were treated equally with addition of ursodeoxycholic acid (15 mg/kg/day). Response to treatment was assessed according to ESPGHAN criteria. (23) Mycophenolate mofetil or a calcineurin inhibitor was used as second-line treatment when standard immunosuppression failed. The 232 patients followed for up to 42 years were divided in three groups: good responders (GRs; 137, 59%) achieved remission (normal transaminase and IgG levels) and maintained it long term, with or without minor, easily treatable, transaminase flares (less than twice the upper limit of normal); suboptimal responders (SRs; 45, 19.4%), comprising 21 who did not achieve complete remission despite response to treatment and 24 frequent relapers (up to 4 relapses per decade with transaminase levels more than twice the upper limit of normal), experienced liver disease progression not requiring liver transplant (LT);(29) and patients with end-stage liver disease (ESLD; 50, 21.5%), including 44 who required LT and 6 who died before LT. Transplant-free survival tended to be higher in AIH-1 than in AIH-2 (P = 0.06) (Fig. 1A).

**HLA ALLELES CONFERRING SUSCEPTIBILITY TO AILD**

The frequencies of 5 HLA class I alleles, 9 HLA class II alleles, and two haplotypes conferring susceptibility or resistance to AILD, chosen from 20 published reports since 1991 (Supporting Table S1), were compared to local controls (Table 2). Frequencies significantly different from local controls are presented in Fig. 2. The authenticity of the local controls was confirmed by comparing their HLA profiles to those of the three national control groups (Supporting Table S2), though the frequencies of five individual HLA alleles and the two haplotypes were not available in the national control groups. The significance of the frequency of HLA alleles was confirmed after Bonferroni correction.

Children with AIH-1 possessed more frequently HLA A*01 and B*8 than HCs. DRB1*03 was more frequent in patients with AIH-1 than in those with ASC and AIH-2. The frequency of homozygous DRB1*03 was higher in patients with AIH-1 than in HCs.

Possession of HLA B*08 and homozygosity for DRB1*03 were more frequent in patients with ASC than in HCs. Frequencies of DRB1*13 and of DRB1*13 in DRB1*03-negative patients were higher in patients with ASC than in HCs and patients with AIH-2.

Patients with AIH-2 were more frequently positive for DRB1*03 or homozygous for DRB1*03 than HCs. There was an overrepresentation of HLA DRB1*07 in patients with AIH-2 compared to HCs and patients with AIH-1 or ASC. The frequency of DRB1*07 in DRB1*03-negative patients was significantly higher in patients with AIH-2 than in HCs and patients with AIH-1 or ASC.

DRB3*0101, which encodes DR52a, was more frequent in patients with AIH-1 and ASC than in HCs. DQB1*0201 was more frequent in patients with AIH-1, ASC, and AIH-2 than in HCs.

The A*01-B*08-DRB1*03 haplotype was more frequent in patients with AIH-1, ASC, and AIH-2 than in HCs. The frequency of B*08-DRB1*03-DQB1*0201 (DQ2) tended to be higher in patients with AIH-1 (37%) than in HCs (22%, P = 0.04 without Bonferroni correction).

Homozygosity for DRB1*03 conferred the highest risk for patients with AIH-1, ASC, and AIH-2 (RR,
Among patients negative for DRB1*03, the possession of DRB1*07 conferred the highest risk for AIH-2 (RR, 3.72), and possession of DRB1*13 conferred a risk for ASC (RR, 2.58). Possession of the A1-B8-DR3 haplotype conferred RRs of 3.28, 2.13, and 2.53 for AIH-1, ASC, and AIH-2, respectively.

For HLA genes conferring resistance to AILD (Fig. 2), DRB1*04, an AIH-susceptibility allele in adult AIH-1, was less frequent in patients with AIH-1 and ASC than in HCs. Among HLA DRB1*03-negative patients, the frequency of DRB1*04 in AIH-1 was comparable to that in HCs, while it was lower in patients with ASC than in HCs.

Two genes, DRB1*15 and DQB1*0302 (DQ8), previously reported to confer resistance to AIH in adults, were also found less frequently in children with AILD than in HCs. Patients with AIH-2 had a DQ8 frequency similar to that of HCs.

No significant differences in the HLA profile were detected in patients with AIH-1 or ASC divided according to presence or absence of IBD (Supporting Table S3).

FIG. 1. Transplant-free survival curves of children with AILD with different HLA genotypes. The association of HLA DRB1* genotypes and transplant-free survival was calculated by Kaplan-Meier survival plot. The x-axis shows the year of survival, defined as the years from diagnosis until the time of LT or death, cutoff at year 20; and the y-axis shows the percentage of survival. (A) Overall survival in the different subgroups of AILD independently from HLA genotype. The survival rate in AIH-1 tended to be higher than in AIH-2 ($P = 0.06$). (B–E) Survival according to HLA DRB1* genotypes in AIH-1, AIH-2, and ASC, respectively. No significant difference in survival was observed among subgroups of patients with AILD.
**TABLE 2. Frequencies of HLA class I and II alleles and haplotypes in 236 patients with AILD and HCs**

| HLA Allele Alleotypes | A1H-1, n = 100, n (%) | P* (P) | RR | ASC, n = 77, n (%) | P* (P after BC) | RR | A1H-2, n = 59, n (%) | P* (P) | RR | Local HCs, n = 209 (%) |
|------------------------|-----------------------|---------|----|-------------------|-----------------|----|---------------------|---------|----|----------------------|
| A*01                   | 55 (55)               | 0.00013 (0.0026) | 1.72 | 37 (48)           | 0.01 (NS)       | 1.50 | 26 (44)             | NS      | 1.38 | 67 (32)              |
| A*02                   | 41 (41)               | NS      | 0.82 | 32 (42)           | NS              | 0.84 | 24 (41)             | NS      | 0.82 | 104 (50)             |
| B*07                   | 16 (15)               | NS      | 0.58 | 20 (26)           | NS              | 1.01 | 11 (19)             | NS      | 0.72 | 54 (26)              |
| B*08                   | 63 (63)               | 7.9E-11 (1.58E-9) | 2.80 | 36 (47)           | 6.0E-5 (0.0012) | 2.08 | 25 (42)             | 0.0013 (0.037) | 1.88 | 47 (22)              |
| B*14                   | 5 (5)                 | NS      | 0.55 | 5 (7)             | NS              | 0.71 | 9 (15)              | NS      | 1.68 | 19 (9)               |
| DRB1*03                | 70 (70)               | 7.6E-11 (1.52E-9) | 2.61 | 32 (42)           | 0.016 (NS)      | 1.55 | 25 (42)             | 0.013 (NS) | 1.58 | 56 (27)              |
| DRB1*03/03             | 17 (17)               | 8.2E-7 (1.65E-5) | 8.88 | 11 (14)           | 3.1E-5          | 7.46 | 6 (10)              | 0.0024 (0.048) | 5.31 | 4 (2)                |
| DRB1*04                | 22 (22)               | 0.021 (NS) | 0.63 | 10 (13)           | 0.00029 (0.006) | 0.37 | 14 (24)             | NS      | 0.68 | 73 (35)              |
| DRB1*04 in DRB1*03 –ve | 11/30 (37)           | NS      | 1.06 | 5/45 (11)         | 0.0023 (0.046) | 0.32 | 8/44 (24)           | NS      | 0.68 | 53/153 (35)          |
| DRB1*07                | 21 (21)               | NS      | 1.19 | 12 (16)           | NS              | 0.88 | 31 (53)             | 1.84E-8 (3.67E-7) | 2.97 | 37 (18)              |
| DRB1*07 in DRB1*03 –ve | 9/30 (30)            | NS      | 1.58 | 8/45 (18)         | NS              | 0.94 | 24/34 (71)          | 1.59E-9 (3.2E-8) | 3.72 | 29/153 (19)          |
| DRB1*13                | 19 (19)               | NS      | 1.02 | 24 (31)           | 0.02 (NS)       | 1.67 | 9 (15)              | NS      | 0.82 | 39 (19)              |
| DRB1*13 in DRB1*03 –ve | 8/30 (27)            | NS      | 1.63 | 19/45 (42)        | 0.0035 (0.01)  | 2.58 | 7/64 (21)           | NS      | 1.26 | 25/153 (16)          |
| DRB1*15                | 7 (7)                 | 0.0018 (0.036) | 0.33 | 9 (12)            | 0.065 (NS)      | 0.55 | 5 (7)               | 0.027 (NS) | 0.4 | 44 (21)              |
| DRB3*0101 (DRB52a)    | 15/19 (79)            | 1.7E-6 (3.5E-5) | 3.21 | 9/14 (64)         | 1.74E-3 (0.035) | 2.61 | 7/20 (35)           | NS      | 1.42 | 33/134 (25)          |
| DQB1*0201 (DQ2)       | 22/30 (73)            | 0.0023 (0.046) | 1.70 | 27/41 (66)        | 0.0092 (NS)     | 1.53 | 19/27 (70)          | 0.0085 (NS) | 1.64 | 68/158 (43)          |
| DQB1*0302 (DQ8)       | 2/31 (7)             | 0.00146 (0.029) | 0.18 | 1/41 (2)          | 2.4E-5 (0.00028) | 0.068 | 7/27 (26)           | NS      | 0.72 | 57/158 (36)          |
| Haplotypes             |                       |         |     |                   |                 |     |                     |         |     |                      |
| A1-B8-DR3              | 44 (44)               | 2.7E-9 (5.4E-8) | 3.28 | 22 (29)           | 0.0027 (0.05)  | 2.13 | 20 (34)             | 2.87E-4 (0.0057) | 2.53 | 28 (13)              |
| B8-DR3-DQ2             | 11/30 (37)            | 0.04 (NS) | 1.7 | 11/41 (27)        | NS              | 1.25 | 9/25 (36)           | NS      | 1.67 | 34/158 (22)          |

RRs higher than 2 and lower than 0.5 are shown in bold. Overrepresented alleles are shown in bold. Underrepresented alleles are shown in italic bold.

*P values compare patients and local HCs. A-L: P values comparing among A1H-1, ASC, and A1H-2: A: A1H-1 vs. ASC, P = 0.03 (NS) and vs. A1H-2, P = 0.01 (NS); B: A1H-1 vs. A1H-2, P = 0.027 (NS); C: A1H-1 vs. ASC, P = 1.47E-5 (0.00029) and vs. A1H-2, P = 5.99E-4 (0.012); D: A1H-1 vs. ASC, P = 0.0081 (NS); E: A1H-2 vs. A1H-1, P = 4.2E-5 (0.00084) and A1H-2 vs. ASC, P = 4.35E-6 (8.7E-5); F: A1H-2 vs. A1H-1, P = 0.0019 (0.038) and vs. ASC, P = 2.2E-6 (4.4E-5); G: ASC vs. A1H-1, P = 0.06 (NS) and vs. A1H-2, P = 0.03 (NS); H: ASC vs. A1H-2, P = 0.04 (NS); I: A1H-1 vs. A1H-2, P = 0.00567 (NS); ASC vs. A1H-2, P = 0.09; J: A1H-1 vs. ASC, P = 0.02 (NS), A1H-2 vs. ASC, P = 0.064; K:A1H-1 vs. A1H-2, P = 0.04 (NS); ASC vs. A1H-2, P = 0.0037 (0.074); L: A1H-1 vs. ASC, P = 0.03 (NS).

Abbreviations: BC, Bonferroni correction; NS, not significant.
ASSOCIATIONS BETWEEN HLA DRB1* GENOTYPES AND CLINICAL FEATURES

To address the impact of the HLA susceptibility DRB1* allotypes on clinical features, response to treatment, and outcome, patients with AILD were divided according to positivity for DRB1*03, homozygosity for DRB1*07 or DRB1*13, or “other DRs,” including DRB1*01, -04, -09, -10, -11, -12, -14, and -15, which could not be analyzed individually owing to their low frequency (Table 2 and Fig. 2; Supporting Tables S4-S6).

UNDIVIDED AILD

Among undivided AILD, age at diagnosis was higher in patients possessing heterozygous or homozygous DRB1*03 or DRB1*13 than in patients with DRB1*07 or “other DRs” (Table 3). Female gender was more frequent in the DRB1*07-positive group than in patients possessing other HLA types. Acute presentation was more frequent in DRB1*07-positive than in DRB1*13-positive patients. Higher baseline AST levels were seen in patients possessing DRB1*03 (heterozygous or homozygous) or DRB1*07 compared to DRB1*13-positive patients and in patients heterozygous for DRB1*03 compared to those with “other DRs.” Higher bilirubin levels were found in patients possessing heterozygous DRB1*03 compared to DRB1*13-positive patients; bilirubin levels were also higher in DRB1*07-positive patients than in those with homozygosity for DRB1*03 or with DRB1*13. The highest alkaline phosphatase (AP) levels were seen in patients heterozygous for DRB1*03 or with DRB1*13 compared to “other DRs.” Gamma-glutamyltransferase (GGT) levels were higher in DRB1*13-positive patients than in homozygous DRB1*03, in DRB1*07, or in “other DR” patients. IgG levels in patients heterozygous/homozygous for DRB1*03 were higher than in those with other HLA types. ANA titers in patients homozygous for DRB1*03 or positive for DRB1*07 were higher than in those with “other DRs.” The highest titers of SMA were seen in patients possessing DRB1*07 and DRB1*13. In patients with AIH, the median HAI was similar among those possessing different HLA class II alleles. However, the median fibrosis score was higher in patients homozygous for DRB1*03 or
TABLE 3. Demographic data of 236, clinical data at diagnosis of 208,* and outcome of 232 patients with AILD according to HLA DRB1* allotypes

| Features           | Median (Range) | DRB1*03 Heterozygous (DR3), n = 57 | DRB1*03 Homozygous (DR3/DR3), n = 33 | DRB1*07 (DR7), n = 58 | DRB1*13 (DR13), n = 45 | Other DRB1* Allotypes, n = 43 | Comparisons | P       |
|--------------------|----------------|------------------------------------|-------------------------------------|-----------------|----------------|---------------------------|-------------|---------|
| Age (years)        | 10.76 (4.3-16) | 11.2 (3.8-17)                      | 9.11 (2.2-16)                       | 11.7 (2.3-15.4) | 8.49 (2.1-15)  |                           | DR3 vs. DR7 | 0.009 |
|                    |                |                                    |                                     |                 |                |                           | DR3 vs. DR13 | 0.03  |
|                    |                |                                    |                                     |                 |                |                           | DR3 vs. other DRs | 0.05  |
|                    |                |                                    |                                     |                 |                |                           | DR3/DR3 vs. DR7 | 0.0056 |
| Female (%)         | 60             | 61                                 | 79                                  | 53              | 58             |                           | DR3/DR3 vs. other DRs | 0.01  |
|                    |                |                                    |                                     |                 |                |                           | DR13 vs. other DRs | 0.02  |
| Acute presentation | 56             | 61                                 | 67                                  | 44              | 56             |                           | DR3 vs. DR13 | 0.03  |
|                    |                |                                    |                                     |                 |                |                           | DR3 vs. other DRs | 0.05  |
|                    |                |                                    |                                     |                 |                |                           | DR3/DR3 vs. DR13 | 0.04  |
|                    |                |                                    |                                     |                 |                |                           | DR3/DR3 vs. other DRs | 0.053 |
|                    |                |                                    |                                     |                 |                |                           | DR7 vs. DR13 | 0.05  |
|                    |                |                                    |                                     |                 |                |                           | DR7 vs. DR3 | 0.045 |
|                    |                |                                    |                                     |                 |                |                           | DR7 vs. DR3/DR3 | 0.02  |
|                    |                |                                    |                                     |                 |                |                           | DR7 vs. DR13 | 0.03  |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR13 | 0.03  |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR7 | 0.03  |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR13 | 0.03  |
| AST (IU/L; nv ≤ 50) | 603 (53-6,600) | 664 (60-2,725)                     | 549 (51-2,642)                     | 475 (84-2,950)  | 270 (62-4,830) | DR3 vs. DR7, DR13, DR13, other DRs | 0.05      |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR7 | 0.03  |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR13 | 0.002 |
|                    |                |                                    |                                     |                 |                |                           | NS         |
| Total bilirubin (μmol/L; nv ≤ 20) | 61 (5-367) | 43 (6-268)                         | 62 (9-445)                         | 49 (9-382)     | 38 (4-379)    | DR3 vs. DR3, DR7, DR13, DR13, other DRs | 0.05 |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR7 | 0.03  |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR13 | 0.03  |
| AP (IU/L; nv ≤ 130) | 323 (66-859) | 295 (64-1,000)                     | 227 (33-1,578)                     | 335 (77-1,115) | 218 (73-1,243) | DR3 vs. DR7, DR3, DR13, other DRs | 0.05 |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR7 | 0.03  |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR13 | 0.03  |
|                    |                |                                    |                                     |                 |                |                           | NS         |
| GGT (IU/L; nv ≤ 55) | 99 (13-656) | 83 (13-469)                        | 65 (6-623)                         | 102 (23-516)   | 72 (20-591)   | DR3 vs. DR7, DR3, DR13, other DRs | 0.05 |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR7 | 0.03  |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR13 | 0.03  |
|                    |                |                                    |                                     |                 |                |                           | NS         |
| IgG (g/L; nv 5-18) | 23 (9.13-68.9) | 26.2 (9.3-68.58)                   | 20.4 (4.65-58)                     | 19.9 (9.4-53.6) | 17.3 (7.81-40.4) | DR3 vs. DR7, DR3, DR13, other DRs | 0.035, 0.037, 0.002 |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR7 | 0.016, 0.014, 0.0017 |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR13 | 0.0017 |
| ANA titer†         | 80 (neg-2,560) | 120 (neg-2,560)                    | 160 (neg-10,240)                   | 40 (neg-2,560)  | 40 (neg-1,280) | DR3 vs. DR7, DR3, DR13, other DRs | 0.03 |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR7 | 0.03 |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR13 | 0.03 |
| SMA titer†         | 40 (neg-2,560) | 120 (neg-2,560)                    | 160 (neg-10,240)                   | 40 (neg-2,560)  | 40 (neg-1,280) | DR3 vs. DR7, DR3, DR13, other DRs | 0.03 |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR7 | 0.03 |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR13 | 0.03 |
| Diagnostic score   | 11 (7-14)      | 11 (7-14)                          | 10 (7-14)                          | 10 (7-14)      | 9 (7-14)      | DR3 vs. other DRs          | 0.01 |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR7 | 0.03 |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR13 | 0.03 |
| HAI (for AIH-1 and AIH-2 only) | 7 (1-17) | 8 (2-17)                            | 8 (2-17)                           | 7 (1-16)       | 8 (2-18)      | DR3 vs. other DRs          | 0.01 |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR7 | 0.03 |
|                    |                |                                    |                                     |                 |                |                           | Other DRs vs. DR13 | 0.03 |

* n = 208 includes patients with follow-up data; † ANA and SMA titer data were available for 208 patients.
### TABLE 3. Continued

| Features                      | Median (Range) | DRB1*03 Heterozygous (DR3), n = 57 | DRB1*03 Homozygous (DR3/DR3), n = 33 | DRB1*07 (DR7), n = 58 | DRB1*13 (DR13), n = 45 | Other DRB1* Alleles, ‡ n = 43 | Comparisons | \( P \) |
|-------------------------------|----------------|------------------------------------|--------------------------------------|-----------------------|-----------------------|-------------------------------|-------------|--------|
| Fibrosis score (for AIH-1 and AIH-2 only) | 3 (0-6) | 5 (2-6) | 3 (1-5) | 5 (0-6) | 3 (0-6) | DR3/DR3 vs. DR3, DR7, other DRs | 0.01, 0.01 | 0.017 |
| Time to achieve biochemical remission (months) | 3.8 (1-12) | 4 (1-14) | 5 (0-5-36) | 6.5 (1-48) | 3 (1-12) | DR3 vs. DR7, DR13 | 0.0015, 0.0019 | 0.035, 0.014, 0.034 |
| GRs, n (%)                    | 43 (78) | 16 (50) | 27 (47) | 24 (49) | 27 (69) | Other DRs vs. DR3/DR3 | 0.06, 0.01, 0.02 | 0.0008 |
| Total = 137                  |              |                                  |                                     |                       |                       | DR3 vs. DR3/DR3 | 0.0066 | 0.0019 |
| SR+FR, n (%)                  | 2 (4) | 11 (34) | 18 (32) | 12 (25) | 2 (5) | Other DRs vs. DR13 | 0.000758 | 0.0019 |
| Total = 45                    |              |                                  |                                     |                       |                       | Other DRs vs. DR3/DR3 | 0.0559 | 0.0001 |
| ESLD n (%)                    | 10 (19) | 5 (16) | 12 (21) | 13 (27) | 10 (26) | DR3 vs. DR7 | 0.001 | 0.0187 |
| Total = 50                    |              |                                  |                                     |                       |                       | Other DRs vs. DR3/DR3 | 0.015 | 0.0001 |
| SR + ESLD, n (%)              | 12 (22) | 16 (50) | 30 (53) | 25 (51) | 12 (31) | DR3 vs. DR13 | 0.0136 | 0.0187 |
| Abbreviations: FR, frequent relapers; neg, negative; NS, not significant; nv, normal value. |

*Transaminase, bilirubin, and IgG values and autoantibody titers of 28 patients treated with immunosuppression longer than 3 months before referral are not included in this table.

†Titers are shown as reciprocal values.

‡Patients with DRB1*01, 04, 09, 10, 11, 12, 14, and 15.
positive for *DRB1*13 than in those possessing heterozygous *DRB1*03, *DRB1*07, or “other DRs.”

Time to remission was shorter in patients heterozygous or homozygous for *DRB1*03 and in those with “other DRs” than in those with *DRB1*07 or *DRB1*13. The percentage of GRs was similar among those heterozygous for *DRB1*03 and “other DRs,” being higher than in patients homozygous for *DRB1*03, *DRB1*07, or *DRB1*13. The percentage of SRs was lower among patients heterozygous for *DRB1*03 or with “other DRs” than in those homozygous for *DRB1*03, *DRB1*07, or *DRB1*13. The percentage of patients with ESLD was similar among the groups, but when SRs and patients with ESLD were considered together their percentage was lower among those heterozygous for *DRB1*03 or “other DRs” than in those homozygous for *DRB1*03, *DRB1*07, or *DRB1*13. Transplant-free survival was similar among patients possessing different HLA genotypes (Fig. 1B).

**AIH-1**

In patients with AIH-1, mode of presentation, frequency of female gender, baseline transaminase and bilirubin levels, and HAI were similar among those possessing different HLA *DRB1* alleles (Supporting Table S4). Patients with heterozygous or homozygous *DRB1*03 and *DRB1*13 were older and had higher IgG levels and median SMA titers at presentation than those with “other DRs.” In heterozygous *DRB1*03-positive patients, levels of AP were higher than in those possessing “other DRs”; GGT levels were higher in heterozygous *DRB1*03-positive patients than in those with *DRB1*07 or with “other DRs” and in homozygous *DRB1*03-positive patients than in those with “other DRs.” The highest ANA titers were seen in patients with homozygous *DRB1*03.

Time to remission was shorter in patients heterozygous for *DRB1*03 and “other DRs” than in patients homozygous for *DRB1*03, *DRB1*07, or *DRB1*13. The median fibrosis score was higher in patients with AIH homozygous for *DRB1*03 and in those positive for *DRB1*13 than in those possessing heterozygous *DRB1*03, *DRB1*07, or “other DRs.”

The percentage of GRs was similar in patients with heterozygous and homozygous *DRB1*03 or “other DRs,” being higher than in patients with *DRB1*07 or *DRB1*13. The percentage of SRs+ESLD was lower in those heterozygous for *DRB1*03 than in those with *DRB1*07 or *DRB1*13. The highest percentage of patients requiring transplant or dying was seen among those possessing *DRB1*13. Transplant-free survival was similar among patients possessing different HLA genotypes (Fig. 1C).

**AIH-2**

In patients with AIH-2, the proportion of females, mode of presentation, levels of IgG, and LKM-1 titers were similar among those with different HLA allotypes (Supporting Table S5). Patients with *DRB1*13 were older than patients possessing other allotypes. The highest AST levels were seen in patients heterozygous for *DRB1*03 and in patients with *DRB1*07 or “other DRs,” reaching statistical significance when patients with *DRB1*07 or “other DRs” were compared to homozygous *DRB1*03. Baseline bilirubin levels were higher in patients with *DRB1*07 and “other DRs” compared to homozygous *DRB1*03. Baseline GGT levels were higher in *DRB1*13 patients compared to those with all other HLA allotypes. The highest HAI was seen in patients with “other DRs” and the lowest with *DRB1*13.

*DRB1*13-positive patients required longer time to achieve remission than patients heterozygous or homozygous for *DRB1*03 with *DRB1*07 or “other DRs.” The median fibrosis score was higher in patients with AIH-2 homozygous for *DRB1*03 or positive for *DRB1*13 than in those possessing heterozygous *DRB1*03, *DRB1*07, or “other DRs.”

The lowest proportion of GRs was seen among patients with homozygous *DRB1*03 or positive for *DRB1*13. Most patients with heterozygous *DRB1*03 or “other DRs” responded well to treatment. The percentage of SR+ESLD was lower in those heterozygous for *DRB1*03 (30%) or with “other DRs” (33%) than in those with homozygous *DRB1*03 (58%), *DRB1*07 (52%), or *DRB1*13 (58%); but the difference was not statistically significant due to the small case number. Transplant-free survival was similar among patients possessing different HLA genotypes (Fig. 1D).

**ASC**

In patients with ASC, mode of presentation and titers of SMA antibodies were similar among the different HLA allotypes (Supporting Table S6). Patients with “other DRs” or with *DRB1*07 were younger...
than patients with heterozygous DRB1*03. There were more female patients among those possessing DRB1*07 than among those with all other HLA alleles. Baseline AST levels were higher in patients homozygous for DRB1*03 or with DRB1*07 than in those with “other DRs.” The highest levels of AP and GGT were seen in patients possessing DRB1*07. IgG levels in patients homozygous for DRB1*03 and in those with DRB1*07 were similar, being higher than in those possessing other HLA alleles. ANA titers in patients homozygous for DRB1*03 or with DRB1*07 were higher than in those with DRB1*13 or “other DRs.”

Time to remission in patients heterozygous or homozygous for DRB1*03 or with “other DRs” was shorter than in those with DRB1*07 or DRB1*13. The percentage of GRs was similar among patients with heterozygous DRB1*03 or with “other DRs,” being higher than in patients with homozygous DRB1*03 or with DRB1*07. All patients with heterozygous DRB1*03 or “other DRs” responded well to treatment. The percentage of SR+ESLD was similar among heterozygous DRB1*03 and “other DRs,” being lower than in those homozygous for DRB1*03 or positive for DRB1*07. Transplant-free survival was similar among patients possessing different HLA genotypes (Fig. 1E).

Discussion

We report the largest study of HLA association in juvenile AILD, with the longest follow-up. We included only children of European ancestry, and owing to the single-center nature of the study, all were rigorously phenotyped and divided into the three main groups of juvenile autoimmune liver disease: AIH-1, AIH-2, and ASC.

We found that HLA B*08, -DRB1*03, and the A1-B8-DR3 haplotype, known to predispose to adult AIH-1, also predispose to all three types of childhood AILD. Because in populations of European ancestry the A1-B8-DR3 haplotype does almost invariably include DRB3*0101 (DR2a) and DQB1*0201 (DQ2), not surprisingly we found that DR2a and DQ2 also predispose to juvenile AILD. Genes that were underrepresented in children with AILD, indicating their protective role, were DRB1*04 (DR4), a susceptibility gene in adult AIH-1,(32) DRB1*1501 (DR2), which protects against AIH also in adults(1); and DQB1*0302 (DQ8), a gene reported to predispose to autoimmunity when associated to DR4.(33) A genome-wide association study in a large number of adult patients from northern Europe(33) reported an association between AIH-1 and possession of both DRB1*03 and DRB1*04. However, the latter was associated with later-onset disease, confirming previous reports(34) and in keeping with the lack of association, indeed protection, we observed between possession of DR4 and the juvenile form of the disease. Interestingly, DR4 has been reported to be associated with AIH susceptibility only in DR3-negative adult patients(1) and to predispose to a later age at onset and less severe disease. This observation has led to the suggestion that AIH in adults may consist of two distinct diseases with distinct HLA associations. In support of this hypothesis, DR3/DR4 heterozygosity in adults was not associated with susceptibility. Similarly, we found no evidence that possession of DR3/DR4 predisposes to AIH in children: only a small number of our patients possess DR3/DR4 (12% of AIH-1 and 10% of AIH-2), and clinical features and outcomes of these patients are similar to those who are DR3/DR4-negative. If DR4 does predispose to a distinct form of late-onset AIH, it is not surprising that it does not predispose to juvenile AILD. DR4 protection against juvenile AILD could derive either from an unrelated HLA association with a disease distinct from adult AIH or from DR4 binding an autoantigenic peptide and preventing it from binding to DR3 or another allotype containing the shared epitope, such as DR52a.

We have also defined individual disease risk alleles for each subgroup of AILD—HLA DRB1*03 for AIH-1, DRB1*13 for ASC, and DRB1*07 for AIH-2—indicating that the three conditions are nosologically distinct entities. These results are in partial agreement with previous studies in smaller pediatric cohorts.

Pediatric AIH-1 has been associated to HLA DRB1*03(20,21) pediatric AIH-2 to possession of HLA DRB1*07(35-37) and in DR7-negative patients, DRB1*0301.(38) In Egypt, AIH-2 has been associated also with the presence of HLA DRB1*15.(36) In Brazil and in Egypt, the primary susceptibility allele for AIH-1 appears to be DRB1*1301, the allele that we find in association with ASC, though a secondary association with DRB1*0301 has also been reported.(36,39) Importantly, however, not all patients in
these reports had undergone cholangiographic studies to exclude bile duct disease. Intriguingly, in South America, HLA DRB1*1301 has been reported to predispose to childhood AIH-1 as well as to persistent HAV infection, suggesting a possible link between the two conditions.\(^{11,40}\)

A follow-up extending to 42 years has allowed us to define HLA alleles associated to disease severity: possession of heterozygous DRB1*03 or “other DRs” predicts a form of AILD better controlled by immunosuppressive treatment than DRB1*03 homozygosity or possession of DRB1*07 or DRB1*13. DRB1*03 homozygosity and possession of DRB1*13 are associated with established liver fibrosis at disease onset and a more severe disease. Possession of these allotypes might account for the third of patients who have established cirrhosis at disease onset.\(^{20,41}\) Although DR3-positive patients appear to have a more active liver disease, as judged by higher autoantibody titers and higher IgG levels at disease onset, akin to the report by de Boer et al.\(^{42}\) in adult patients with AIH-1, they had a better initial response to immunosuppression with a shorter time to achieve biochemical remission and tended to maintain remission long term and relapse less frequently than those possessing DRB1*07 and DRB1*13 alleles. Interestingly, patients possessing heterozygous DRB1*03 genes progressed less frequently to ESLD than those with DRB1*07 or DRB1*13. At variance with our findings, Junge et al.\(^{43}\) suggested that DR3-positive children with AILD are less likely to reach remission. However, no accepted criteria for remission were used in their small cohort of ethnically mixed patients. In a large Dutch cohort of adult patients with AIH-1, HLA-DRB1*03:01 was also found to be the strongest genetic modifier of disease severity, while HLA DRB1*13 was not investigated\(^{3}\) because it had not been previously found to be associated with AIH-1 in the Netherlands, although the population studied was similar to ours, being of European ancestry.

We do show that possession of homozygous DRB1*03 influences disease severity and response to treatment, the frequency of GRs being lower in homozygous than heterozygous DRB1*03 patients. Relevantly, in a family study, we noted that the strongest predisposition to juvenile AILD is homozygosity for HLA DRB1*03 because it was more frequent in affected children than in their first-degree relatives and in HCs, the only first-degree relative affected by AILD (primary sclerosing cholangitis [PSC]) in the whole cohort sharing HLA DRB1*03 homozygosity with his proband brother, who had ASC.\(^{44}\)

Most patients with AIH-2 responded well to immunosuppressive treatment initially, but fewer of them could stop immunosuppression compared to AIH-1. This may be due to the frequent possession of DRB1*07 that was present in 71% of patients with AIH-2 when those who were DRB1*03-positive were excluded. DRB1*07-positive patients with AIH-2 presented with the highest AST and bilirubin levels at diagnosis and responded to immunosuppression less frequently compared to patients possessing other types of HLA genes. A similarly lower response rate was observed in DRB1*07-positive patients with AIH-1 or ASC. Preliminary data from our laboratory show that DRB1*07-positive patients have an impairment of cluster of differentiation 4-positive (CD4\(^{\text{pos}}\)) CD25\(^{\text{high}}\)CD127\(^{\text{low/}}\text{forkhead box P3–positive regulatory T cells, both at disease onset and during remission, when compared to patients possessing DRB1*03, DRB1*13, or “other DRs,” suggesting that possession of DRB1*07 lessens control over autoimmunity.

The relationship between juvenile ASC, which has overlapping features with AIH-1, and adult PSC, both strongly associated with IBD, remains unclear. The HLA profile of ASC, while partially overlapping with AIH-1, also shows dissimilarities as up to one third of patients with ASC are positive for DRB1*13, this proportion being even higher among those negative for DRB1*03, indicating that DRB1*13 is a risk gene (RR, 2.6) for ASC. The similarities between juvenile ASC and adult PSC extend to HLA because both conditions share predisposing HLA genes, like B*08, DRB1*03, DRB1*13, and A1-B8-DR3 haplotype,\(^{45}\) suggesting that at least some adult patients with PSC might have an immunologically burnt-out end-stage form of juvenile ASC. Possession of DRB1*13 in adult PSC is associated with more severe liver disease, a greater need for LT, and decreased graft survival.\(^{46,47}\) In our cohort, DRB1*13-positive patients with ASC responded to immunosuppression less well than those possessing DRB1*03 genes.

An external validation cohort of carefully phenotyped (i.e., with cholangiographic studies to differentiate between AIH-1 and ASC) patients with AIH-1, AIH-2, and ASC recruited prospectively would be desirable to confirm our data. It would, however, require decades to recruit patients with these
rare conditions and obtain the relevant follow-up information.

In summary, we have defined both HLA class I and II profiles for each subgroup of childhood AILD: DRB1*03 for AIH-1, DRB1*03 plus DRB1*07 for AIH-2, and DRB1*13 for ASC. DRB1*03 and the A1-B8-DR3 haplotype are disease-predisposing genes for all three subgroups. The influence of HLA class II genes on disease severity is strong, DRB1*03 homozygosities and possession of DRB1*13 being associated to histologically more advanced disease from onset, while DRB1*07 is linked to the least optimal response to immunosuppression. The influence of the distinct HLA genes on effector and regulatory immune responses in the different AILD subgroups should be further explored.

Acknowledgment: We thank Dr. Alex Knisely for contributing to liver histology assessment.

Author Contributions: Y.M., H.S., M.S., D.V., and G.M.V. were responsible for study design, writing, and critically reading the manuscript. Y.M., M.Y., M.S.L., M.M., H.S., P.W., J.G., and D.G.D. were responsible for HLA typing and analyzing the data. S.B., G.W.W., and M.S. provided clinical data. A.Q. and Y.Z. provided and assessed histological data. M.M., D.G.D., R.T., L.Y., N.H., and M.H. critically read through the manuscript and added intellectual content.

REFERENCES

1) Doherty DG, Donaldson PT, Underhill JA, Farrant JM, Duthie A, Miel-Ver-Gani G, et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994;19:609-615.
2) Baharlou R, Faghihi-Kashani A, Faraji F, Najafi-Samei M, Setareh M, Zamani F, et al. HLA-DRB1 alleles of susceptibility and protection in Iranians with autoimmune hepatitis. Hum Immunol 2016;77:330-335.
3) van Gerven NMF, de Boer YS, Zwiers A, Verwer BJ, Drenth JPH, van Hook B, et al. HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. Genes Immun 2015;16:247-252.
4) Yoshizawa K, Ota M, Katsuyama Y, Ichijo T, Matsumoto A, Tanaka E, et al. Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis. J Hepatol 2005;42:578-584.
5) Boberg KM. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis 2002;6:635-647.
6) Vízquez-García MN, Álvez C, Olivo A, Debaz H, Pérez-Luque E, Burgue A, et al. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol 1998;28:985-990.
7) Mendoza-Carrera F, Gastelum-Meza MÁ, Ramírez-García J, Dávalos-Cobián C, Castro-Martínez XH, Arellano-Olivera M, et al. No association of HLA-DRB1 and TNF alleles in Mexican patients with autoimmune hepatitis. Genes Immun 2019;20:678-683.
8) Umemura T, Yoshizawa K, Saito H, Yoshizawa K, Norman GL, Tanaka E, et al. KIR/HLA genotypes confer susceptibility and progression in patients with autoimmune hepatitis. J Hepatol 2019;1:353-360.
9) Strettell MD, Donaldson PT, Thomson LJ, Santrach PJ, Moore SB, Czaja AJ, et al. Allergic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997;12:2028-2035.
10) Pando M, Larriba J, Fernandez GC, Fainboin H, Ciocca M, Ramonet M, et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999;30:1374-1380.
11) Donaldson PT. Immunogenetics in liver disease. Baillieres Clin Gastroenterol 1996:10:533-549.
12) Donaldson PT. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut 2004;53:599-608.
13) Fortes MDP, Machado IV, Gil G, Fernández-Mestre M, Daquer L, León RV, et al. Genetic contribution of major histocompatibility complex class II region to type 1 autoimmune hepatitis susceptibility in Venezuela. Liver Int 2007;27:1409-1416.
14) Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544-553.
15) Donaldson PT, Doherty HG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R, Williams R susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991;13:701-706.
16) Muratori P, Czaja AJ, Muratori L, Pappas G, Maccariello S, Cassani F, et al. Genetic distinctions between autoimmune hepatitis in Italy and North America. World J Gastroenterol 2005;11:1862-1866.
17) Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 1993;18:816-822.
18) Oertinger R, Brunnberg A, Gerner P, Wintermeyer P, Jenke A, Wirth S. Clinical features and biochemical data of Caucasian children at diagnosis of autoimmune hepatitis. J Autoimmun 2005;24:79-84.
19) Nunes MEG, Rosa DV, Fagundes EDT, Ferreira AR, Miranda DM, Ferri Liu PM. HLA-DRB1 gene polymorphisms in pediatric patients with type 1 autoimmune hepatitis and type 1 autoimmune hepatitis overlap syndrome with autoimmune cholangitis. Arq Gastroenterol 2019;56:146-150.
20) Donaldson PT. Genetics in autoimmune hepatitis. Semin Liver Dis 2002;22:353-364.
21) Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25:541-547.
22) du Montcel ST, Michou L, Petit-Teixeira E, Orsorio J, Lemaire I, Lasbleiz S, et al. New classification of HLA-DRB1 alleles supports the shared epitope hypothesis of rheumatoid arthritis susceptibility. Arthritis Rheum 2005;52:1063-1068.
23) Miel-Ver-Gani G, Vergani D, Baumann U, Czubkowski P, Debray D, DezoI A, et al. Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN hepatology committee position statement. J Pediatr Gastroenterol Nutr 2018;66:345-360.
24) Klouda PT, Molnar J, Wasik A, Bodmer JG, eds. HLA-A, B, and DR antigens in the British Isles. Bristol: UKTS Publications; 1985:1-48.
25) Darke C, Guttridge MG, Thompson J, McNamara S, Street J, Thomas M. HLA class I (A, B) and II (DR, DQ) gene and haplotype frequencies in blood donors from Wales. Exp Clin Immunogenet 1998;15:69-83.
26) Brown J, Pola E, Brown CJ, Contreras M, Navarrete CV. HLA-A, -B and -DR antigen frequencies of the London Cord Blood Bank units differ from those found in established bone marrow donor registries. Bone Marrow Transplant 2000;25:475-481.
27) Donaldson PT, Norris S. Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis. Autoimmunity 2002;35:555-564.
28) Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
29) Hoeroldt B, McFarlane E, Dube A, Basumani P, Karajeh M, Campbell MJ, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011;140:1980-1989.
30) Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;65-70.
31) Greenland S. Interpretation and choice of effect measures in epidemiologic analyses. Am J Epidemiol 1987;125:761-768.
32) Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001;96:1224-1231.
33) Mangalam AK, Taneja V, David CS. HLA class II molecules influence susceptibility versus protection in inflammatory diseases by determining the cytokine profile. J Immunol 2013;190:513-519.
34) Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006;43:532-538.
35) Bittencourt PL, Goldberg AC, Cançado EL, Porta G, Laudanna AA, Kalil J. Different HLA profiles confer susceptibility to autoimmune hepatitis type 1 and 2. Am J Gastroenterol 1998;93:1394-1395.
36) Elfaramawy AAM, Elhossiny RM, Abbas AA, Aziz HMA. HLA-DRB1 as a risk factor in children with autoimmune hepatitis and its relation to hepatitis A infection. Ital J Pediatr 2010;36:73.
37) Djilali-Saiah I, Renous R, Caillat-Zucman S, Debray D, Alvarez F. Linkage disequilibrium between HLA class II region and autoimmune hepatitis in pediatric patients. J Hepatol 2004;40:904-909.
38) Ma Y. Bogdanos DP, Hussain MJ, Underhill J, Bansal S, Longhi MS, et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006;130:868-882.
39) Oliveira LC, Porta G, Marin MLB, Bittencourt PL, Kalil J, Goldberg AC. Autoimmune hepatitis, HLA and extended haplotypes. Autoimmun Rev 2011;10:189-193.
40) Fainboim L, Cañero Velasco MC, Marcos CY, Ciocca M, Roy A, Theiler G, et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB1*1301, a marker for pediatric autoimmune hepatitis. Hepatology 2001;33:1512-1517.
41) Mieli-Vergani G, Heller S, Jara P, Vergani D, Chang M-H, Fijisawa T, et al. Autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2009;49:158-164.
42) de Boer YS, van Gerven NM, Zwiens A, Verwer BJ, van Hoek B, van Erpemck J, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 2014;147:443-452.e5.
43) Junge N, Tiedau M, Verboom M, Hallensleben M, Blasczyk R, Schlué J, et al. Human leukocyte antigen and pediatric autoimmune liver disease: diagnosis and prognosis. Eur J Pediatr 2016;175:527-537.
44) Wang P, Su H, Underhill J, Blackmore LJ, Longhi MS, Grammatikopoulos T, et al. Autoantibody and human leukocyte antigen profiles in children with autoimmune liver disease and their first-degree relatives. J Pediatr Gastroenterol Nutr 2014;58:457-462.
45) Pollheimer MJ, Hallibasic E, Fickert P, Trauner M. Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2011;25:727-739.
46) Futagawa Y, Waki K, Kai J. The association of HLA-DR13 with lower graft survival rates in hepatitis B and primary sclerosing cholangitis Caucasian patients receiving a liver transplant. Liver Transpl 2006;12:600-604.
47) Fosby B, Ness S, Hov JR, Traherne J, Boberg KM, Trowsdale J, et al. HLA variants related to primary sclerosing cholangitis influence rejection after liver transplantation. World J Gastroenterol 2014;20:3986-4000.

Supporting Information

Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.31893/suppinfo.